Paul D. Bryson

Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis

Shirit Einav, Doron Gerber, Paul D. Bryson et al. · Nature Biotechnology · 2008 · 228 citations · Full text

Microfluidic Affinity Analysis, Pharmaceutical Research, Engineering +12

Masked Chimeric Antigen Receptor for Tumor-Specific Activation

Xiaolu Han, Paul D. Bryson, Yifan Zhao et al. · Molecular Therapy · 2017 · 110 citations · Full text

Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers

Elizabeth L. Siegler, Xianhui Chen, Natnaree Siriwon et al. · Molecular Therapy · 2017 · 101 citations · Full text

In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia

Cheng Zhi, Runhong Wei, Qiuling Ma et al. · Molecular Therapy · 2018 · 89 citations · Full text

Identification of a Class of HCV Inhibitors Directed Against the Nonstructural Protein NS4B

Nam‐Joon Cho, Hadas Dvory‐Sobol, Choongho Lee et al. · Science Translational Medicine · 2010 · 58 citations · Full text